600 patients66,869 observations120 daysLIVE

Patient P-01854

Synthetic patientNBL-101 · Day 96 · 25–34 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 47 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 67 ME-01 recommendedMonitoring Escalation ME-01
  4. Day 68 Patient acceptedStarted ME-01 in the companion
  5. Day 71 Deterioration detected before clinical escalationMonitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 47.

Primary contributors, last 14 days
  • GI instability+16
  • Toxicity-10
  • Inflammatory activity+9
  • Nutritional resilience-6
  • Treatment adherence+6

What helped?

  • Monitoring Escalation ME-01Day 67
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 83% showed improvement
  • median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
84.1/100
worsening · +16.0 vs previous 14 d
Toxicity
Blood
53.7/100
worsening · +2.3 vs previous 14 d
Sleep quality
Wearable
19.8/100
worsening · -5.3 vs previous 14 d
Energy level
Daily log
1.4/10
worsening · -0.8 vs previous 14 d
Stress level
Daily log
8.4/10
worsening · +0.9 vs previous 14 d
Steps
Wearable
1,229
worsening · -737 vs previous 14 d
Adherence
Companion
43.4 %
worsening · -15.9 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 29 from the failing basin, 92 from restoration.

Would help
  • GI-04 GI Support Protocol
    73% improved among 124 similar · onset 8 d · confidence 97%
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 71%
  • SC-12 Supportive Compound
    76% improved among 51 similar · onset 6 d · confidence 71%
Would not help
  • Keep fat low
    GI +5.4 next day on high-intake days · n 25
  • Keep histamine low
    GI +5.1 next day on high-intake days · n 25
  • Keep simple carbs low
    GI +4.8 next day on high-intake days · n 22
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +5.4detractor · 95%
  • Histamine load
    +5.1detractor · 95%
  • Simple carbohydrates
    +4.8detractor · 95%
  • Spicy / capsaicin
    +3detractor · 65%
  • Alcohol
    -0.2no signal · 15%
  • Insoluble fibre
    -0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Inflammatory signalling 85
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 77
    • WearableHRV 18 ms, trending down
  • Mucosal barrier integrity 80
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 84 and rising
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 30/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Autonomic recovery 65
    • WearableResting HR 89 bpm
    • Wearable1,229 steps/day
    • WearableShort sleep window
  • Drug metabolism and exposure 20
    • BloodToxicity index 54
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Rapid metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.3 · butyrate capacity 30/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
15 ms
Sleep
6.3 h
Steps
887
Resting HR
88 bpm
Daily log: GI score 84, nutritional resilience 24, adherence 43.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0181337%S01NP-02no change40
P-0132729%S01GI-04improved56
P-0131026%S0157
P-0168825%S01GI-04improved40
P-0187724%S01CR-01improved67
P-0182117%S0158
P-0182317%S0157
P-0160416%S0171
P-0145228%S02GI-04improved46
P-0163526%S02GI-04improved49
P-0145924%S0251
P-0149817%S0256